Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

[View interview]

Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer. Scancell Co-Founder and Non-Executive Director Richard Goodfellow tells Proactive why the deal is significant for investors. The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors.

[View interview]

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive Cancer Research UK is to fund and sponsor a Phase I/II clinical trial of their SCIB2 lung cancer vaccine.

Goodfellow says the tie-up is a significant endorsement of their  ImmunoBody platform – the underlying technology behind both SCIB1 and SCIB2 - which helps to prime a patient’s immune system to recognise and kill specific cancer cells.

[View interview]